Redeye is positive about SciBase’s additional order from Castle Biosciences, worth approximately USD0.6m (cSEK5m), as it supports both an acceleration of the ongoing clinical study and preparations for a second study. While the order itself is broadly in line with our expectations, we place greater emphasis on the positive signalling value of continued activity within the collaboration. We make no changes to our estimates and reiterate our Base Case.
LÄS MER
